Please find attached Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026.

4th November, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, 'Exchange Plaza', Sandra Kurla Complex, Fort, Mumbai - 400 001 Sandra (E), Mumbai - 400 051 Scrip Code: 533573 NSE Symbol: APLL TD Dear Sir/ Madam, Sub: Outcome of Board Meeting held on 4th November, 2026 With reference to the captioned matter, the stock exchanges are hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today inter-alia has approved the Consolidated and Standalone Unaudited Financial Results along with the Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended 301h September, 2026. The time of commencement of Board Meeting was 11 :30 a.m. and the time of conclusion was 2:10 p.m. We request you to kindly take the same on record. Thanking you, Yours faithfully, F lembic Pharmaceuticals Limited 1rag K. Shukla Company Secretary Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGO. OFFICE: ALEMBIC ROAD, VADODARA- 390 003. •TEL: (0265) 2280550, 2280880 Website: www.alembicpharmaceuticals.com •E-mail: alembic@alembic.co.in • CIN: L24230GJ2010PLC061123 ALEMBIC PHARMACEUnCAlS UMITTD CIN:l24230Gl2010PLC061123 Regd.Office: Alembic Road, Vadodara · 390 003 Tel : 0265 6637000 Email : apl.investors@alembic.co.in Website : www.alembicpharmaceutieals.com Statement of Consolidated Unaudited Financial Results for the quarter and half year ended :,om septemt>er, 2020 Rs .m. C rores Quarter Ended Half Year Ended Year Ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudlted) (Audited) 1 Revenue from Operations 2,603.48 2,149.77 1,910.15 4,753.25 3,620.87 7,344.90 2 Other Income 15.11 14.93 6.91 30.04 13.41 54.41 3 Total Income 2,618.59 2,164.70 1,917.06 4,783.29 3,634.28 7,399.31 4 Expenses (a) Cost of Materials cnnsumed 599.64 517.30 463.14 1,116.94 894.41 1,747.38 (b) Purchase or stock-In-trade 177.22 120.50 126.82 297.73 235.98 508.88 (c) Changes in Inventories or finished goods, Stock in trade and WIP (91.09) (17.72) (74.04) (108.81) (207.06) (271.81) (d) Employee benefits expense 503.75 473.94 437.54 977.70 860.31 1,731.93 (e) Finance Costs 38.26 27.61 24.23 65.86 47.75 93.63 (f) Depredation &. Amortization Expense 100.80 97.71 76.07 198.52 149.84 318.55 (g) Other Expenses 850.69 723.89 641.00 1,574.58 1,240.19 2,510.06 Total Expenses 2,179.27 1,943.23 1,694.76 4,122.51 3,221.43 6,638.61 Profit before Share of Profit/ (Loss) of Assaciates and Joint 439.31 221.47 222.30 660.79 412.85 760.69 5 Ventures 6 Share or Profit/ (Loss) of Associates Iii Joint Ventures (1.37) 0.39 1.42 (0.98) 0.97 0.24 7 Profit Before Exceptional Item and Tax 437.95 221.86 223.72 659.81 413.82 760.94 - . . . . (66.99) 8 Exceptional Item • Refer Note No. 3 g Profit Before Tax 437.95 221.86 223.n 659.81 413.82 693.95 10 Tax Expense 98.67 44.35 46.59 143.02 68.81 127.60 (i) Current Tax (Ii) Deferred Tax 5.38 5.15 (6.59) 10.52 7.67 (104.48) 11 Profit for the Period before non-controlling interests 333.91 172.36 183.71 506.27 337.34 670.83 1,26 0.71 1.00 1.97 1.75 3.94 12 Non-controlling Interests 13 Profit for the Period after non-controlling interests 335.17 173.07 184.71 508.23 339.09 674.77 14 Other Comprehensive Income A (I) Items that will not be reclassified to profit/ (loss) (2.69) (0.49) (7.18) {3.18) (7.65) (6.96) Income tax relating to items that will not be redassified to profit I 0.68 0.12 1.25 0.80 1.34 0.93 (ll) (loss) B (I) Items that will be reclassified to profit/ (loss) (4.17) 3.14 10.59 (1.04) 11 ..6 9 30.89 (II) Income tax relating to items that will be reclassified to prom: / (loss) 1.14 (0.49) . 0.65 Total Other Comprehensive Income (A+B) (5.05) 2.28 4.67 (2.77) 5.38 24.86 15 Total Comprehensive Income for the period (11+14) 328.86 174.63 188.38 503.50 342.12 695.69 Attributable to: • Non-controlling Interests (1.35) (0.70) (1.10) (2.05) (1.86) (4.41) • Owners of the Company 330.21 175.33 189.49 505.54 344.58 700.09 16 Earnings per share· Basic & Diluted (in Rs.) 17.05 8.80 9.40 25.86 17.25 34.33 17 Paid up Equity Share capital (Face Value of Rs 2/· each) 39.31 39.31 39.31 39.31 39.31 39.31 5,635.50 18 Other Equity Notes: The above consolidated results have been recommended by the Audit Committee and approved by the Board of Directors of the Company. The results have been subjected to review by the statutory auditors of the Company. The report of the statutory auditors Is unqualified. 2 The Company is engaged In Pharmaceuticals business only and therefore, there is only one reportable segment. 3 Exceptional Items for the year ended 31st March 2026 comprised Rs. 48.64 crore relating to employee benefit obligations arising from the revised definition of wages under the Labour Codes, and a write-down of Rs. 18.35 crore on assets of the Sikkim manufacturing facility dassified as held for sale under Ind AS 105. 4 For year ended 31st March 2026, consequent to the Finance Act amendment, the Company reassessed deferred tax assets and tax credits, and the resulting Impact has been recognised as a credit in the Statement of Profit and Loss. 5 DISCiosures as per Regulation 52(4) of the SEBI (Listing Obligations and Dlsdosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder: Quarter Ended Half Year Ended Year Ended S Nr o. Pilrtiailal'5 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 a Debt-Equity Ratio (in times) 0.25 0.28 0.27 0.25 0.27 0.24 Debt/ Net Worth [Debt : Total Debt ( Short tenn + Long term) Net worth : Share Capital + Other Equity) b Debt Service Coverage Ratio (in times) 10.99 7.63 10.23 9.55 9.67 6.91 (Profit before tax+interest) /(Interest+ schedule principal repayments of long term debt) Annualised 12.45 9.04 10.23 U.02 9.67 8.41 C Interest Service Coverage Ratio (in times) (Profit before tax+interest)/ lnterest d Net Worth (Rs. in Crores) 5,950.55 5,856.21 5,322.35 5,950.55 5,322.35 5,680.88 ( Equity capital + Other Equity exduding fair value change on financial e I Cn us mtru ,m nte n Rt as t t ih or o (iu ng h ti mOC eI s) ) 1.69 1.69 1.59 1.69 1.59 1.75 Current Asset/ Current Liabilities f Long Term Debt to working capital (in times) o.os 0.06 0.02 0.05 0.02 0.07 Long Tenn Borrowings (Ind. Current Maturities)/ (Current Assets • Current Liabilities) - . . - 0.04% 0.07% g Bad Debts to Accounts Receivable Ratio {o/o) h CB uad r rD ee nb tt s U/ a bA ic lc ito yu n Rts a tR ioe c (e iniv a tb imle e s) 0.86 0.85 0.89 0.86 0.89 0.84 I C Tu or tr ae ln Dt eL bia tb sil i tt oie Ts o/ tT ao l t Aal s sLi ea tb si li (t Ii ne s t imes) 0.16 0.18 0.18 0.16 0.18 0.16 (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets 6.11 5.20 5.48 s.ss 5.24 5.05 J Debtors Turnover Ratio (in times) (Value of Sales and Service/ Average Debtor) Annualised s.90 5.03 4.90 5.40 4.68 4.67 k Inventory Turnover (in times) (Sale of products/ Average WIP, FG and Stock in trade Inventory) I A On pn eu ra al tis ie nd g Margin (0/o) 22.21•.1, 16.18% 17.02% 19.480/o 16.93% 16.03% EB!TDA (before E><ceptlonal Items)/ ReVenue from OperatiOns m Net Profit Margin(%) 12.870/o 8.05% 9.67% 10.690/o 9.36% 9.19% (Net Profit after taxes and share of Profit/(L<>ss) of Associates and Joint Ventures)/ Revenue ~m Operations ' For Alembic Pharmaceuticals Umited Chirayu Amin Chairman Place : Vadodara Date : 4th November,2026 Visit us at www.atembicpharmaceuticals.com Alembic Pharmaceuticals Limited Rs • in C rores Statement of Assets and Liabilities - Consolidated As at 30th As at 31st September, 2026 March, 2026 Particulars CUnauditedl /Audited\ A ASSETS 1 Non-current assets 2,914,11 2,843.59 (a) Property, plant and equipment 542.84 633.70 (bl capital work-in-progress 327.83 237.08 (c) Other Intangible assets 51,47 49.70 {d) Intangible assets under develo [Showing first 8,000 characters — download PDF for full document]